

L1
CONT.

T cells with the soluble B7 fusion protein and thereby inhibiting T cell proliferation.

L2

¹⁰
w88.

(Amended) A method of inhibiting CD28 positive T cell responses comprising reacting B7 positive B cells with a soluble CD28 fusion protein so as to bind the B7 positive B cells with the soluble CD28 fusion protein thereby inhibiting T cell responses caused by the binding of B7 and CD28.

The amendments to the claims do not contain new material. Support for the amendments can be found in the specification, e.g. at page 46 - 47. Accordingly, the changes to the claims do not involve new matter and entry of these changes is requested.

Claims 79-94 are presently being examined. Reconsideration and withdrawal of all outstanding objections and rejections to the claims are earnestly solicited in view of the changes to the claims hereinabove. Applicants look forward to a favorable action on the merits.

No fee is deemed necessary in connection with the filing of this Supplemental Amendment. If any fee is necessary, the Patent Office is authorized to charge any additional fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
SaraLynn Mandel
Registration No. 31,853
Attorneys for Applicants
Mandel & Adriano
35 N. Arroyo Parkway
Pasadena, California 91103
(626) 395-7801

88

2